Alpha Cognition commercially launches ZUNVEYL to treat mild to moderate AD

Alpha Cognition (ACOG) announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This milestone marks a major step forward in the company’s mission to provide innovative and accessible solutions for patients and caregivers – and to deliver new hope to the millions impacted by Alzheimer’s. With a highly experienced commercial team in place, including industry leaders with proven success in the long-term care market, Alpha Cognition is poised to make a powerful impact. The company’s nationwide salesforce is fully deployed and actively engaging with healthcare providers to ensure that ZUNVEYL reaches the patients who need it most. The commercial strategy is specifically designed to address the unique challenges of the long-term care market, the largest segment for Alzheimer’s disease, and a $2 billion market opportunity. “The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease,” said Lauren D’Angelo, Chief Operating Officer and Chief Commercial Officer of Alpha Cognition. “Our team has worked relentlessly to bring this treatment to market – from building out an industry-leading infrastructure to hiring a top notch sales team – all in record time. I’m incredibly proud of the dedication and expertise of our team, and we are excited to partner with healthcare professionals to ensure that patients receive the care they deserve.”